Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints - Reuters

1. Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints  Reuters
2. Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps in premarket  CNBC
3. Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.  Barron's
4. Novo Nordisk Falls Most on Record After New Weight Drug Disappoints  Bloomberg
5. Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.  Investor's Business Daily